Compugen (CGEN) has just reported its FY 2025 results, with Q3 revenue of US$1.9 million and a basic EPS loss of US$0.07. Trailing twelve month figures show revenue of US$6.9 million and a basic EPS loss of US$0.30. The company has seen quarterly revenue range from US$1.3 million to US$2.3 million in FY 2025 so far, with basic EPS losses between US$0.07 and US$0.08 over the same stretch. This sets up a picture in which top line consistency still sits alongside negative earnings. With revenue growth forecasts and ongoing losses firmly in focus, the key question for investors is how quickly these reported results can translate into healthier margins and a clearer path toward sustainable profitability.

See our full analysis for Compugen.

With the latest numbers on the table, the next step is to see how they line up with the dominant market and community narratives around Compugen, highlighting where expectations match the data and where they may need a rethink.

Losses hover around US$7 million per quarter

• Across FY 2025 so far, net income loss has sat between US$6.98 million and US$7.34 million per quarter, with basic EPS losses between US$0.07 and US$0.08. This shows a fairly tight band of quarterly outcomes rather than big swings.
• Bulls point to the five year trend of loss reduction at 19.3% per year as a sign the business model is moving in the right direction. However, the trailing twelve month net loss of US$27.62 million and an EPS loss of US$0.30 keep the company firmly in loss making territory.
  • That tension is clear when you line up the five year loss improvement against forecasts that still do not show a return to profit within the next three years.
  • For a bullish view to fully play out, those roughly US$7 million quarterly losses would need to narrow further so that any future revenue growth actually shows up in earnings.

Compugen’s bulls argue that improving loss trends and higher growth forecasts set the stage for a stronger story than the recent US$6.98 million quarterly loss suggests, and they lay out in detail how that could translate into future earnings. 🐂 Compugen Bull Case

High P/S multiple with mixed valuation signals

• On the valuation side, Compugen trades on a P/S of 30.5x, compared with 12.5x for the US biotechs industry and 3.7x for peers. The DCF fair value in the dataset is US$25.59 against a current share price of US$2.25, which represents a very large gap between those two yardsticks.
• Consensus narrative highlights a tug of war here, with potential benefits from partnerships and immunotherapy demand set against reliance on milestones and funding. That mix shows up in the numbers as an elevated P/S multiple alongside a DCF fair value that is far above where the stock currently trades.
  • The high P/S suggests the market already prices in strong future revenue, even though the trailing twelve month revenue sits at US$6.90 million and profitability is still negative.
  • The DCF fair value of US$25.59 relies on assumptions about future cash flows that differ significantly from what the current loss of US$27.62 million over twelve months would imply on its own.

Revenue forecasts outpace the wider market

• Revenue is forecast to grow 25.87% per year, ahead of the 10.2% annual forecast for the broader US market. Recent reported revenue has moved between US$1.26 million and US$2.28 million per quarter in FY 2025 and totals US$6.90 million over the last twelve months.
• Consensus narrative sees this faster revenue profile as tied to clinical progress and partnerships, but the same analysis also flags that earnings are not expected to turn positive within three years. The key question becomes how much of that forecast top line growth eventually filters through to margins.
  • The current trailing twelve month net loss of US$27.62 million alongside the forecast revenue growth rate shows that scale alone is not yet closing the gap to profitability.
  • Until earnings move closer to break even, investors are likely to weigh that 25.87% forecast growth against the reality of ongoing losses and the premium 30.5x P/S multiple.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Compugen on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of high growth forecasts and ongoing losses leaves you on the fence, act while the data is fresh and test the numbers yourself. To see how the balance of possible upside and areas of concern stacks up, take a closer look at 2 key rewards and 1 important warning sign.

Explore Alternatives

Compugen combines quarterly losses of roughly US$7 million, a trailing twelve month net loss of US$27.62 million and a 30.5x P/S multiple, with no forecast return to profit within three years.

If those ongoing losses and the premium revenue multiple feel like more risk than you want to carry right now, compare them against 77 resilient stocks with low risk scores that prioritise steadier financial profiles and potentially more predictable outcomes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.